Citius Pharmaceuticals, Inc. (CTXR): Nasdaq/NYSE listing notice — Citius Pharma posts first revenue of $3.9M from LYMPHIR launch; Nasdaq warns of bid price deficiency

Citius Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.38 revenue$3,944,111

Q1 FY2026 revenue $3.9M from initial LYMPHIR sales; net loss $8.2M ($0.41 loss per share).
Cash and equivalents $7.7M; raised ~$20.9M from equity financings in quarter.
Nasdaq notified company of bid price deficiency; has until Aug 10, 2026 to regain compliance.
LYMPHIR launched Dec 2025; early physician adoption; international patient access via Named Patient Programs.
Late-stage pipeline includes Mino-Lok and Halo-Lido; engaging with FDA on next steps.

item 2.02 item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Citius Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 9, 2026, Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until August 10, 2026, to regain compliance with the Bid Price Rule. If at any time before August 10, 2026, the bid price of the Company's co

View on SEC.gov

Browse all listing & compliance notices →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-015895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.